1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsAging Reimagined — New Health Frontiers Grand Challenge is sponsored by Nucleate (in collaboration with Eli Lilly and Company). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Press enter or click to view image in full size **BOSTON, MA — April 15, 2026** — Nucleate today announced the launch of the 2026 Grand Challenge, introducing a new thematic focus: **“Aging Reimagined — New Health Frontiers.
”** Now entering itsfourth year, the Grand Challenge continues to identify and accelerate early-stage biotech innovations — this year concentrating on functional health and resilience across the world’s aging population. To learn more about the challenge, watch last year’srecap video, featuring past participants and winners discussing how the program accelerated their progress and created lasting value.
You can also register for upcoming info sessions featuring previous year’s winnershere. Developed in collaboration with Eli Lilly and Company (Lilly), the 2026 Grand Challenge will spotlight a new generation of therapeutics and technologies aimed at improving how individuals age; not by targeting aging as an abstract concept, but by addressing the measurable, real-world challenges that impact quality of life.
> “The Grand Challenge has become a powerful engine for surfacing early-stage innovation in areas of emerging scientific interest,” said **Debra Luffer-Atlas, Ph. D. , Senior Vice President of Scientific Strategy at Lilly Catalyze360**.
“This year’s focus is on identifying potential opportunities to meaningfully improve health and function over time by targeting the underlying biological mechanisms that shape mobility, cognition, immune resilience, and tissue regeneration. We are excited to engage with founders and help accelerate next-generation research.
” The 2026 Grand Challenge will take place on **September 22, 2026**, at Lilly’s global headquarters in Indianapolis, convening a select cohort of early-stage biotech teams to present their work to Lilly scientists, business leaders, and partners. Selected finalists will have the opportunity to compete for a $100,000 non-dilutive grant while gaining direct mentorship from Lilly’s innovation ecosystem.
This year’s challenge will feature four focused tracks: ● **Mobility & Frailty**: Interventions that improve muscle, bone, and joint function together — targeting frailty, fall risk, and loss of independence. ● **Cognitive & Sensory Health**: Addressing hearing, vision, and cognitive deterioration as an integrated system, with clear functional endpoints.
● **Immune Resilience**: Enhancing immune response in aging populations, including infection recovery and vaccine responsiveness. ● **Regenerative Medicine (Wildcard Track)**: Harnessing cellular, tissue, and biologics-based approaches to restore lost function — targeting wound healing, organ repair, and age-related degeneration with measurable endpoints in tissue integrity and functional recovery.
Together, these tracks reflect a shift toward **healthspan-oriented innovation**, grounded in endpoints that are clinically meaningful and translationally actionable. > “At its core, the Grand Challenge is about identifying and accelerating innovation in areas where new thinking is needed most,” said **Oliver Dodd, Executive Director at Nucleate**.
“This year’s focus on _Aging Reimagined_ allows us to leverage Nucleate’s global network to map emerging whitespace — bringing forward founders who are tackling functional decline in ways that align with real clinical and commercial pathways. ” Applications for the 2026 Grand Challenge are now open, with submissions closing on May 15th, 2026. Apply atthis link to be considered.
The program is open to early-stage biotech founders and researchers worldwide, and affiliation with Nucleate is not required. Nucleate is a nonprofit organization dedicated to empowering the next generation of biotech leaders.
With chapters spanning over 40 global regions and participation from hundreds of academic institutions, Nucleate builds communities that connect emerging talent with the resources, networks, and education needed to launch and scale biotech ventures. Through its programs, Nucleate is democratizing access to biotechnology innovation and enabling founders to develop solutions to the world’s most pressing health challenges.
Learn more atwww. nucleate. org.
According to the current listing, eligibility includes: Early-stage biotech teams and founders with innovations in functional health and resilience for the aging population. Confirm the full requirements in the official notice before applying.
The current listing shows $100,000 (non-dilutive grant for finalists). Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was September 22, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Aging Reimagined — New Health Frontiers Grand Challenge is funded by Nucleate (in collaboration with Eli Lilly and Company). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The Eli Lilly and Company Foundation's 2026 Open Call opened June 1 and closes July 3, across three focus areas: Global Health, K-12 STEM Education, and Economic Mobility. But two of the three only fund Marion County, Indiana. Here is how to read the geographic fine print, why the funder's commercial identity shapes what wins, and how to position a proposal that actually fits.
Read articleWith Forms J in FY2027, NIH will no longer accept letters of support — the boilerplate endorsements applicants have padded proposals with for decades. Notice NOT-OD-26-094 replaces them with letters of collaboration, aligning NIH with NSF. Here is exactly what changes, what a compliant letter must now contain, who can no longer write one, and how this fits the broader re-engineering of the NIH application package.
Read articleOMB and roughly 40 agencies have proposed the most sweeping overhaul of 2 CFR Part 200 in more than a decade. Political appointees would pre-review notices of funding opportunity and discretionary awards, agencies gain near-unappealable 'national interest' termination authority, and federal funds can no longer support collaborations with covered foreign entities. The rule drew nearly half a million comments and is slated to take effect October 1, 2026. Here is what actually changes, who is exposed, and how to write proposals that survive the new regime.
Read article